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Oxytocin and Dopamine Stimulate Ghrelin Secretion
by the Ghrelin-Producing Cell Line, MGN3-1 in Vitro
Hiroshi Iwakura, Hiroyuki Ariyasu, Hiroshi Hosoda, Go Yamada, Kiminori Hosoda,
Kazuwa Nakao, Kenji Kangawa, and Takashi Akamizu
Ghrelin Research Project (H.I., H.A., T.A.), Translational Research Center, and Department of Medicine
and Clinical Science, Endocrinology, and Metabolism (G.Y., K.H., K.N.), Kyoto University Hospital, Kyoto
University Graduate School of Medicine, Kyoto 606-8507, Japan; and National Cerebral and
Cardiovascular Center Research Institute (H.H., K.K.), Osaka 565-8565, Japan
To understand the physiological role of ghrelin, it is crucial to study both the actions of ghrelin and
the regulation of ghrelin secretion. Although ghrelin actions have been extensively revealed, the
direct factors regulatingghrelin secretionbyghrelin-producingcells (X/A-like cells), however, isnot
fully understood. In this study, we examined the effects of peptide hormones and neurotransmit-
ters on in vitro ghrelin secretion by the recently developed ghrelin-producing cell line MGN3-1.
Oxytocin and vasopressin significantly stimulated ghrelin secretion by MGN3-1 cells. Because
MGN3-1 cells express only oxytocin receptormRNA, not vasopressin receptormRNA, oxytocin is the
likely regulator, with the effect of vasopressin mediated by a cross-reaction. We also discovered
thatdopamine stimulates ghrelin secretion fromMGN3-1 cells in a similarmanner to thepreviously
known ghrelin stimulators, epinephrine and norepinephrine. MGN3-1 cells expressed mRNA en-
coding dopamine receptors D1a and D2. The dopamine receptor D1 agonist fenoldopam stimu-
lated ghrelin secretion, whereas the D2, D3 agonist bromocriptine did not. Furthermore, the D1
receptor antagonist SKF83566 attenuated the stimulatory effect of dopamine. These results indi-
cate that the stimulatory effect of dopamine on ghrelin secretion ismediated by the D1a receptor.
In conclusion, we identified two direct regulators of ghrelin, oxytocin and dopamine. These find-
ings will provide new direction for further studies seeking to further understand the regulation of
ghrelin secretion, which will in turn lead to greater understanding of the physiological role of
ghrelin. (Endocrinology 152: 2619–2625, 2011)
Ghrelin is a stomach-derived 28-amino acid peptidehormone with a unique modification of acylation,
first described by Kojima et al. in 1999 (1). To understand
better the physiological function of ghrelin, it is crucial to
study both ghrelin action and the regulation of ghrelin
secretion. The actions of ghrelin have been vigorously in-
vestigated by multiple groups, revealing a wide variety of
activities, including GH-stimulating (2), orexigenic (3),
fat-storing (4), cardiovascular (5), gastroprokinetic (6),
and insulin-suppressing (7) activities. In contrast, the reg-
ulation of ghrelin secretion from ghrelin-producing cells
(X/A-like cells) is not fully understood. Although the re-
sults of in vivo studies suggest that plasma ghrelin levels
are regulated by acute and chronic energy status (8–10),
the individual factors regulating ghrelin secretion by ghre-
lin-producing cells (X/A-like cells) remains unclear due to
the lack of an appropriate in vitro assay system.
Recently we established a ghrelin-producing cell line,
MGN (mouse ghrelinoma) 3-1 cells from a gastric ghreli-
noma isolated from ghrelin promoter SV40-T antigen
transgenic mice (11, 12). TheMGN3-1 cell is the first cell
line derived from a gastric ghrelin-producing cell that pre-
serves the ability to secrete of substantial amounts of ghre-
lin under physiological regulation, making this line one of
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.
Copyright © 2011 by The Endocrine Society
doi: 10.1210/en.2010-1455 Received December 20, 2010. Accepted April 6, 2011.
First Published Online April 26, 2011
Abbreviations: ANP, Atrial natriuretic peptide; AVP, vasopressin; CNP, C-type natriuretic
peptide; C-RIA, anti-COOH-terminal ghrelin (amino acids 13–28) antiserum used to detect
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the best research tools to study the regulation of ghrelin
secretion in vitro. In previous studies, we used MGN3-1
cells to examine the effects of insulin and somatostatin,
which are well established in in vivo studies to suppress
ghrelin secretion (13–16). In this study, we examined the
effects of peptide hormones and nonpeptide neurotrans-
mitters on in vitro ghrelin secretion from MGN3-1 cells.
Materials and Methods
Cell culture
MGN3-1 cells were cultured in DMEM supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 g/ml
streptomycin at 37 C in 10% CO2 as described previously (12).
Batch incubation study
MGN3-1 cells were seeded at 7.5 105 cells/well and cultured
for 24 h in 12-well plates. After a washing with PBS, cells were
incubated at 37C for 4 h inDMEMsupplementedwith 0.5%BSA
andthe indicated reagentsbefore collecting supernatants.Toscreen
for peptide hormones stimulating or suppressing ghrelin secretion,
IGF-I, glucagon, somatostatin, pancreatic polypeptide (PP), gluca-
gon-like peptide (GLP)-1, secretin, neurotensin, thyroxin, atrial na-
triuretic peptide (ANP), GH (SigmaAldrich Japan, Tokyo, Japan),
gastrin, cholecystokinin (CCK), vasoactive intestinal peptide (VIP),
gastric inhibitory polypeptide (GIP), calci-
tonin, oxytocin, vasopressin (AVP), C-type
natriuretic peptide (CNP) (Peptide institute,
Inc., Osaka, Japan), GH-releasing peptide 2
(GHRP2; Kaken Pharmaceuticals, Co., Ltd,
Tokyo, Japan), insulin (Invitrogen, Carlsbad,
CA), or leptin (Pepro Tech, Inc., Rocky Hill,
NJ) were added to each well at 106 M. To
screen for neurotransmitters, acetylcholine,
nicotine, muscarine, epinephrine, norepi-
nephrine, dopamine, histamine, serotonin,
glutamate, or -aminobutyric acid (GABA;
SigmaAldrichJapan)wereaddedat104Mto
each well. To determine the stimulatory ad-
renergic receptor subtype, 105 M of isopro-
terenol, denopamine, ritodrine, phenyleph-
rine, or clonidine (SigmaAldrich Japan)were
used. To determine the stimulatory dopa-
mine receptor subtype, 105 M apomorphine,
fenoldopam, or bromocriptine (Sigma Aldrich
Japan) were used. For the antagonistic studies,
oxytocin receptor antagonist [d(CH2)5
1,
Tyr(Me)2,Orn8]-oxytocin (Bachem, Buben-
dorf Switzerland), 1-receptor antagonist
atenolol (Sigma Aldrich Japan), and dopamine
D1 receptor antagonist SKF83566 (Tocris Bio-
science, Ellisville,MO) were used.
Measurements of ghrelin
concentrations in culture medium
To measure ghrelin concentrations in
culturemedium, the collected culturemedia
were centrifuged, and the resulting super-
natants were immediately applied to Sep-
Pak C18 cartridges (Waters Corp., Milford, MA) preequili-
brated with 0.9% saline. After washing cartridges with saline
and 5% CH3CN/0.1% trifluoroacetic acid, bound protein was
eluted with 60% CH3CN/0.1% trifluoroacetic acid. Eluates
were lyophilized and subjected to ghrelin RIA. Two types of
ghrelin RIA were performed: C-RIA, in which an anti-COOH-
terminal ghrelin (amino acids 13–28) antiserum is used to detect
both ghrelin and desacyl-ghrelin, and N-RIA, in which an anti-
NH2-terminal ghrelin (amino acids 1–11) antiserum detects
ghrelin only, as described (17, 18).
RT-PCR and quantitative RT-PCR
Total RNA was extracted using an RNeasy kit (QIAGEN,
Hilden, Germany). Reverse transcription was performed with
a high-capacity cDNA reverse transcription kit (Applied Bio-
systems, Foster City, CA). RT-PCR was performed using a
GeneAmp 9700 cycler (Applied Biosystems) with AmpliTaq
Gold using appropriate primers (Supplemental Table 1, pub-
lished on The Endocrine Society’s Journals Online web site at
http://endo.endojournals.org). Real-time quantitative PCR
was performed using an ABI PRISM 7500 sequence detection
system (Applied Biosystems) using appropriate primers and
taqman probes or Power SybrGreen (Supplemental Table 1).
The mRNA expression of each gene was normalized to the























































































































































































































FIG. 1. The effects of peptide hormones on ghrelin secretion by MGN3-1 cells. A and B, The
amount of ghrelin secreted by MGN3-1 cells incubated for 4 h in DMEM supplemented with
0.5% BSA and 106 M GH, GHRP2, IGF-I, insulin, glucagon, somatostatin, PP, gastrin, CCK,
GLP-1, VIP, GIP, secretin, neurotensin, calcitonin, oxytocin, AVP, T4, leptin, ANP, or CNP. **,
P  0.01 in comparison with controls (n  9).
2620 Iwakura et al. Oxytocin and Dopamine Stimulate Ghrelin Endocrinology, July 2011, 152(7):2619–2625
Statistical analysis
All values were expressed as the means  SE. The statistical
significance of the differences in mean values was assessed by
ANOVA with a post hoc test (Turkey’s test) or Student’s t test as
appropriate. Differences with P  0.05 were considered significant.
Statistical analysiswasperformedbyStatcel2 (OMS,Saitama, Japan).
Results
Effects of peptide hormones on ghrelin secretion
First, we examined the effects of various peptide hor-
mones on ghrelin secretion by MGN3-1 cells. Oxytocin
and vasopressin significantly stimulated ghrelin secretion
by MGN3-1 cells, whereas insulin and somatostatin sup-
pressed the secretion as reported previously (12) (Fig. 1, A
and B). Addition of any of the other peptides, including
GH, GHRP2, IGF-I, glucagon, PP, gastrin, CCK, GLP-1,
VIP, GIP, secretin, neurotensin, calcitonin, thyroxin, lep-
tin, ANP, or CNP to the medium had no effect on ghrelin
secretion (Fig. 1, A and B).
MGN3-1 cells expressedmRNAencoding the oxytocin
receptor but did not express mRNA for any subtypes of
vasopressin receptors (types 1a, 1b, and 2; Fig. 2A), indi-
cating that the stimulatory effect of va-
sopressin is likely secondary to a cross-
reaction to the oxytocin receptor.
Actually, addition of oxytocin receptor
antagonist [d(CH2)5
1,Tyr(Me)2,Orn8]-
oxytocin significantly attenuated the
stimulatoryeffectofvasopressinonghre-
lin secretion (Fig. 2, B and C). Oxytocin-
mediated stimulation of ghrelin-secre-
tionwas dose dependent (ED50 value for
N-RIA: 51.22 nM; C-RIA: 21.9 nM; Fig.
2, D and E). Although oxytocin induced
a small, but significant, increase in ghre-
lin O-acyltransferase (GOAT) mRNA
levels in MGN3-1 cells (Fig. 2F), ghrelin




Wenext examined the effects ofnon-
peptide neurotransmitters on ghrelin
secretion byMGN3-1 cells. Ghrelin se-
cretion by MGN3-1 cells was stimu-
lated by the addition of epinephrine,
norepinephrine, or dopamine to the
medium (Fig. 3, A and B). No effects on
ghrelin secretionwere seen after the ad-
dition of acetylcholine, nicotine, mus-
carine, histamine, serotonin, gluta-
mate, or GABA to the medium (Fig. 3, A and B). Ghrelin
secretion induced by epinephrine increased in a dose-de-
pendent manner (ED50 value for N-RIA: 1.31M; C-RIA:
2.36M;Fig. 4,AandB).MGN3-1 cells expressedmRNA
encoding of 1a- and 1-adrenergic receptors (Fig. 4C).
The nonselective -agonist isoproterenol and the 1-ag-
onist denopamine significantly stimulated ghrelin secre-
tion by MGN3-1 cells (Fig. 4, D and E). The 2-agonist
ritodrine also stimulated ghrelin secretion to a lesser extent,
whichmayhavebeen secondary to cross-reactivity (Fig. 4,D
and E). No effect on ghrelin secretion was found using the
1-agonist phenylephrine, the 1a-agonist A61603 or the
2-agonist clonidine (Fig. 4,DandE).Additionof1-receptor
antagonist atenolol significantly attenuated the stimulatory ef-
fect of epinephrine onghrelin secretion (Fig. 4, F andG).These
results indicate that the stimulation of ghrelin secretion by epi-
nephrine or norepinephrine is primarily mediated by the 1-
receptor. Isoproterenol significantly increased GOAT mRNA
levels but not ghrelin mRNA levels (Fig. 4, H and I).
The stimulation of ghrelin secretion by dopamine was
also dose dependent (ED50 value for N-RIA: 24.7 M;
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FIG. 2. The effect of oxytocin on ghrelin secretion by MGN3-1 cells. A, RT-PCR analysis of
oxytocin receptor (Oxy-R) and vasopressin receptors (AVPR) 1a, 1b, and 2 mRNA expression in
MGN3-1 cells. B and C, The amount of ghrelin secreted by MGN3-1 cells incubated for 4 h in
DMEM supplemented with 0.5% BSA and 106 M AVP with or without 106 M
[d(CH2)5
1,Tyr(Me)2,Orn8]-oxytocin (oxytocin receptor antagonist). **, P  0.01 in comparison
with controls; ##, P  0.01 in comparison with AVP (n  9). D and E, The amount of ghrelin
secreted by MGN3-1 cells incubated for 4 h in DMEM supplemented with 0.5% BSA and
108 to 106 M oxytocin. **, P  0.01 in comparison with controls () (n  9). F and G,
Ghrelin and GOAT mRNA levels in MGN3-1 cells after a 24-h incubation with 106 M
oxytocin. **, P  0.01 in comparison to controls (n  9). AU, Arbitrary unit.
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mRNA encoding dopamine receptors D1a and D2 (Fig.
5C).Thenonselectivedopamine receptor agonist apomor-
phine and the D1 receptor agonist fenoldopam also sig-
nificantly stimulated ghrelin secretion from MGN3-1
cells, whereas the D2, D3 agonist bromocriptine had no
effect (Fig. 5, D and E). Addition of D1
receptor antagonist SKF83566 signifi-
cantly attenuated the stimulatory effect
of dopamine on ghrelin secretion (Fig.
5, F and G). These results indicate that
the stimulatory effect of dopamine on
ghrelin secretion ismediatedby theD1a
receptor. Apomorphine had no effect
on ghrelin or GOAT mRNA levels in
MGN3-1 cells (Fig. 5, H and I).
Discussion
Ghrelin-producing cells are located in
the stomach. These cells secrete ghrelin
by responding to various kinds of in-
puts, possibly hormones, neurotransmitters, or nutrients.
From these exogenous signals, the cell can sense the
outside environment and/or interact with other organs








































































































































































FIG. 3. The effects of neurotransmitters on ghrelin secretion by MGN3-1 cells. A and B, The
amount of ghrelin secreted by MGN3-1 cells incubated for 4 h in DMEM supplemented with
0.5% BSA and 104 M acetylcholine, nicotine, muscarine, epinephrine, norepinephrine,
dopamine, histamine, serotonin, glutamate, or GABA. **, P  0.01 in comparison with
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FIG. 4. The effects of epinephrine on ghrelin secretion by MGN3-1 cells. A and B, The amount of ghrelin secreted by MGN3-1 cells incubated for
4 h in DMEM supplemented with 0.5% BSA and 107 to 105 M epinephrine. **, P  0.05, **, P  0.01 in comparison with controls () (n  9).
C, RT-PCR analysis of adrenergic receptors-1a, -1b, -1d, -2a-c, and -1–3 mRNA expression in MGN3-1 cells. D and E, The amount of ghrelin
secreted by MGN3-1 cells incubated for 4 h in DMEM supplemented with 0.5% BSA and 105 M isoproterenol (-agonist), denopamine (1-
agonist), ritodrine (2-agonist), phenylephrine (1-agonist), clonidine (2-agonist), or A61603 (1a-agonist). **, P  0.01 in comparison with
controls (n  9). F and G, The amount of ghrelin secreted by MGN3-1 cells incubated for 4 h in DMEM supplemented with 0.5% BSA and 105 M
epinephrine with or without 104 M atenolol (1-antagonist). **, P  0.01 in comparison with controls; ##, P  0.01 in comparison with
epinephrine (n  9). H and I, Ghrelin and GOAT mRNA levels in MGN3-1 cells after a 24-h incubation with 105 M isoproterenol. *, P  0.05 in
comparison with controls (n  9). AU, Arbitrary unit.
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which in turn influences various homeostatic systems,
including energy homeostasis or growth control. We
sought to understand better the molecular mechanisms
governing ghrelin secretion by cells, which may further
contribute to understanding the physiological role of
ghrelin. In previous studies, we have developed a ghre-
lin-secreting cell line MGN3-1 as a research tool to
study the regulation of ghrelin secretion in vitro (12). In
this study, we examined the effects of the various pep-
tide hormones and neurotransmitters on ghrelin secre-
tion using MGN3-1 cells.
We found that oxytocin signific-
antly stimulates ghrelin secretion from
MGN3-1 cells. Oxytocin, a nonapep-
tide with a disulfide bond, is secreted
from the posterior pituitary gland in a
neuroendocrinemannerand is involved
in milk ejection and uterine contrac-
tion. Oxytocin also acts as a neu-
rotransmitter, specifically as a negative
regulator of food intake to oxytocin-
receptive neurons in the paraventricu-
lar nucleus of the hypothalamus (19).
Only two previous reports have exam-
ined the effect of oxytocin on plasma
ghrelin levels. Vila et al. (20)described a
reduction in basal and lipopolysaccha-
ride-induced ghrelin levels in healthy
men after systemic administration of
oxytocin. Shibata et al. (21) reported
that inhibition of the suckling-induced
increase in plasma oxytocin levels by a
oxytocin antagonist did not alter
plasma ghrelin levels in lactating rats.
Although the investigators concluded
that oxytocin has no effects on ghrelin
secretion, our findings are not in accor-
dance with that report. The reason for
this discrepancy is not clear but may
result from indirect effects of additional
mediators in vivo. Further studies will
be needed to explore the regulation of
ghrelin secretion by oxytocin in vivo.
We also found that the nonpeptide
neurotransmitters epinephrine and nor-
epinephrinestronglystimulateghrelinse-
cretionbyMGN3-1 cells. Ghrelin secre-
tion has been suggested to be regulated
by the sympathetic nervous system.
Mundinger et al. (22) noted that in-
creased portal ghrelin levels in rats after
electrical sympathetic nerve stimula-
tion or iv tyramine administration.Ho-
soda and Kangawa (23) reported that the administration
of adrenergic agonists increased plasma ghrelin levels in
rat. Recently Zhao et al. (24) reported that ghrelin secre-
tion from the pancreatic ghrelinoma cell line PG-1 and the
stomach ghrelinoma cell line SG-1 could be stimulated by
1-adrenergic receptors. Our observation demonstrating
increased ghrelin secretion after epinephrine and norepi-
nephrine administration is consistent with these results,
supporting the idea that sympathetic nervous system is an
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FIG. 5. The effect of dopamine on ghrelin secretion by MGN3-1 cells. A and B, The amount
of ghrelin secreted by MGN3-1 cells incubated for 4 h in DMEM supplemented with 0.5%
BSA and 106 to 104 M of dopamine. *, P  0.05, **, P  0.01 in comparison with controls
() (n  9). C, RT-PCR analysis of dopamine receptor (DR) D1a and D2–5 mRNA expression in
MGN3-1 cells. D and E, The amount of ghrelin secreted by MGN3-1 cells incubated for 4 h in
DMEM supplemented with 0.5% BSA and 105 M apomorphine (nonselective dopamine
agonist), fenoldopam (D1 agonist), or bromocriptine (D2, D3 agonist). **, P  0.01 in
comparison with controls (n  9). F and G, The amount of ghrelin secreted by MGN3-1 cells
incubated for 4 h in DMEM supplemented with 0.5% BSA and 104 M dopamine with or
without 104 M SKF83566 (D1 antagonist). **, P  0.01 in comparison with controls; ##,
P  0.01 in comparison with dopamine (n  9). H and I, Ghrelin and GOAT mRNA levels in
MGN3-1 cells after a 24-h incubation with 105 M apomorphine (n  9). AU, Arbitrary unit.
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In addition to epinephrine and norepinephrine, dopa-
mine also significantly stimulated ghrelin secretion from
MGN3-1 cells via the D1A receptor. As far as we know,
this is the first report of ghrelin secretion stimulation by
dopamine. Dopamine is a catecholamine, acting as a neu-
rotransmitter in the certain brain areas inmotor control or
reward behaviors. A substantial amount of dopamine is
also produced in the gastrointestinal tract (25), inwhich it
suppresses gastricmotility, stimulates exocrine secretions,
modulates jejunal sodium absorption, or protects against
gastroduodenal ulcers (26, 27).Our finding raises the pos-
sibility that gastrointestinal dopamine may also control
ghrelin secretion.
In this study, we used a standard culture medium
(DMEM) for the incubation study. The medium contains
several compounds including inorganic salts, glucose,
amino acids, or vitamins, the concentrations ofwhichmay
not be entirely the same to that around the ghrelin cell in
vivo. We cannot exclude the possibility that these com-
pounds may have influenced on the results and that may
explain the discrepancy between our data and clinical
studies of oxytocin. Further studies will be needed to clar-
ify the combinational effects of these compounds in the
medium and peptide hormones or neurotransmitters.
In addition to epinephrine and norepinephrine, which
were previously known to increase ghrelin secretion, we
identified two new regulators of ghrelin secretion, oxyto-
cin and dopamine, by screening peptide hormones and
neurotransmitters using MGN3-1 cells. These findings
will provide new direction for further studies seeking to
understand better the regulation of ghrelin secretion and
the overall physiological role of ghrelin in organism ho-
meostasis and energy regulation.
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